GlassScriptPhysician profile
Gina Brown
NPI 1295881977
$1,521.09
in general payments reported to CMS, 2019-2025
19 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $116 · 2021: $230 · 2022: $216 · 2023: $192 · 2024: $252 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.37 |
| Education | $138.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $382.59 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $333.97 | 2021-2024 | Skyrizi, Humira, Rinvoq |
| Genzyme Corporation | $230.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $88.96 | 2019-2025 | |
| Chiesi USA, INC. | $68.23 | 2025 | Filsuvez |
| Pfizer INC. | $56.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $52.88 | 2019-2020 | |
| Ucb, INC. | $46.09 | 2019-2023 | Bimzelx |
| Leo Pharma INC. | $40.57 | 2022-2024 | Adbry |
| Amgen INC. | $39.16 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $37.18 | 2019 | |
| Dermavant Sciences, INC. | $24.91 | 2023 | Vtama |
| Dusa Pharmaceuticals, INC. | $22.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.54 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $17.81 | 2024 | Zoryve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $17.07 | 2025 | Vyjuvek |
| Janssen Biotech, INC. | $14.95 | 2021 | |
| Galderma Laboratories, L.P. | $14.65 | 2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.